Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

This study is testing a combination of two drugs — eltanexor and venetoclax — in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has come back or stopped responding to previous treatments. Both are targeted cancer drugs that work by blocking proteins that help cancer cells survive. **You may be eligible if...** - You are 18 or older - You have been diagnosed with MDS (with increased blasts) that progressed after treatment, or AML that has relapsed or is no longer responding to therapy - Your liver and kidney function are within acceptable ranges - You have a moderate or better performance level (able to care for yourself) **You may NOT be eligible if...** - You have received cancer treatment within the past 2 weeks - You have had a stem cell transplant within the past 3 months - You have active, uncontrolled infection - You cannot swallow pills - You have active leukemia in the brain or spine - You are pregnant or breastfeeding - You have had a major heart event (heart attack, bypass surgery) in the past 6 months Talk to your doctor to see if this trial is right for you.